Gonadotropin surge-attenuating factor: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 30: | Line 30: | ||
{{Endocrinology-stub}} | {{Endocrinology-stub}} | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
== Gonadotropin surge-attenuating factor == | |||
<gallery> | |||
File:Effects_of_GnSAF_on_early_and_late_follicular_phase.png|Effects of GnSAF on early and late follicular phase | |||
</gallery> | |||
Latest revision as of 01:55, 17 February 2025
Gonadotropin surge-attenuating factor (GnSAF) is a non-steroidal ovarian substance that modulates the bioactivity of gonadotropin-releasing hormone (GnRH). It is believed to play a significant role in the regulation of the female reproductive cycle.
Function[edit]
GnSAF is produced by the ovary in response to stimulation by follicle-stimulating hormone (FSH). It acts on the pituitary gland to attenuate the preovulatory luteinizing hormone (LH) surge. This modulation of LH surge is crucial for the timing of ovulation and the subsequent establishment of pregnancy.
Biochemical Characteristics[edit]
GnSAF is a non-steroidal protein with a molecular weight of approximately 30,000 Daltons. It is heat-stable and resistant to enzymatic digestion. Its exact structure and mechanism of action remain unknown.
Clinical Significance[edit]
Abnormalities in GnSAF production or action may contribute to reproductive disorders such as polycystic ovary syndrome (PCOS) and premature ovarian failure (POF). Further research into GnSAF could lead to new treatments for these and other reproductive disorders.
See Also[edit]
- Gonadotropin-releasing hormone
- Follicle-stimulating hormone
- Luteinizing hormone
- Polycystic ovary syndrome
- Premature ovarian failure
References[edit]
<references />

This article is a endocrinology stub. You can help WikiMD by expanding it!
Gonadotropin surge-attenuating factor[edit]
-
Effects of GnSAF on early and late follicular phase
